FDA Leaders to Headline PDA/FDA Joint Regulatory Conference Session
Senior leaders from three U.S. FDA centers and the Office of Inspections and Investigations will participate in a key session at the 2026 PDA/FDA Joint Regulatory Conference.
Senior leaders from the U.S. Food and Drug Administration's (FDA) centers for drugs, biologics, and veterinary medicine, along with representatives from the Office of Inspections and Investigations, are scheduled to headline a session at the 2026 PDA/FDA Joint Regulatory Conference in Washington D.C. The conference is set to take place on September 14.
The event focuses on current regulatory issues affecting the pharmaceutical, biologics, and veterinary medicine industries. The participation of high-level FDA officials indicates a focus on providing updates and insights into the agency's perspectives on regulatory compliance and future directions.
Co-organized by the Pharmaceutical Development and Manufacturing Association (PDA), the conference serves as a platform for dialogue between industry professionals and regulatory authorities. Discussions are expected to cover advancements in manufacturing practices and regulatory expectations.